Hepatitis B: weighing the costs of treatment.
Angus
Peter W
PW
D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D016527:Drug Costs; D006509:Hepatitis B / Q000188:drug therapy / Q000191:economics*; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D007370:Interferon Type I / Q000191:economics* / Q000627:therapeutic use; D019259:Lamivudine / Q000191:economics* / Q000627:therapeutic use; D008017:Life Expectancy; D011994:Recombinant Proteins
D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D019259:Lamivudine